Seek­ing an edge in the glob­al I/O race, Al­pham­ab On­col­o­gy loads up $100M-plus from mar­quee back­ers

Al­pham­ab On­col­o­gy be­lieves it has what it takes to stand out from the del­uge of check­point in­hibitors cur­rent­ly in de­vel­op­ment — not just in Chi­na but glob­al­ly. A syn­di­cate of well-heeled in­vestors now shares that con­fi­dence, in­fus­ing more than $100 mil­lion to fu­el an am­bi­tious dri­ve through the clin­ic.

Ad­van­tech, PAG and Chi­na Ven­ture Cap­i­tal Fund led the Se­ries A, which is ex­pect­ed to sup­port Al­pham­ab’s lead as­set, KN035, all the way up to reg­is­tra­tional tri­als and fund late-stage pro­grams for three oth­er clin­i­cal drug can­di­dates. Or­biMed, Her­itage Provider Net­work and Jan­chor Part­ners al­so chipped in.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER